FEASIBILITY OF PROLIFERATION STUDIES USING THE BRDU AND MTT ASSAYS WITH A HEAD AND NECK-CARCINOMA CELL-LINE

被引：13

作者：

BERGLER, W

PETROIANU, G

SCHADEL, A

机构：

[1] ENT Department, Klinikum der Stadt Mannheim, University of Heidelberg, Heidelberg

来源：

ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES | 1993年 / 55卷 / 04期

关键词：

CELL PROLIFERATION; MTT ASSAY; BRDU ASSAY;

D O I：

10.1159/000276429

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 [耳鼻咽喉科学];

摘要：

After the failure of interferon monotherapies for head and neck cancer, an increasing number of combination experiments with chemotherapy and interferons have been carried out to improve the antiproliferative effect. In vitro drug testing requires sensitive assay to detect synergistic effects of tested combinations in order not to get false-negative results. The widely used MTT assay (3,4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide) and the BrdU assay 5-bromo-2-deoxyuridine were compared. It could be shown that the BrdU assay is over 10 times more sensitive and that it reflects the cell proliferation status as shown by flow-cytometric analysis using double staining with BrdU. Labeling with BrdU also allows the estimation of the S phase time. Because of the direct effect of interferons on the cell cycle, the BrdU assay could be appropriate for proliferation studies using interferons.

引用

页码：230 / 235

页数：6

共 23 条

[1]

Mosmann T., Rapid colorimeirie assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J Immunol Methods, 65, pp. 55-59, (1983)

[2]

Slater T.F., Sawyer B., Strauli U., Studies on suc-cinate-tetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts, Biochim Biophys Acta, 77, pp. 383-386, (1963)

[3]

Wilson J.K., Sarget J.M., Elgie A.W., Hill J.G., Tayler C.G., A feasibility study of MTT assay for chemosensitivity testing in ovarian malignancy, Br J Cancer, 62, pp. 189-194, (1990)

[4]

Alley M.C., Scudicro D.A., Monka A., Feasibility of drug screening with panels of human tumour cell lines using a microculture tetrazolium assay, Cancer Res, 48, pp. 589-594, (1988)

[5]

Carmichael J., Mitchell J.B., De Graff W.G., Gamson J., Chemosensitivity testing of human lung cancer cell lines using the MTT assay, Br J Cancer, 57, pp. 540-547, (1985)

[6]

Carmichael J., De Graff W.G., Gazdar A.F., Minna J.D., Mitchell J.B., Evaluation of tetrazolium based scmiautomated colorimetric assay. II, Cancer Res, 47, pp. 943-950, (1987)

[7]

Walsh C.H., Speyer J.L., Wemz J., Phase I study of combination of alpha 2 interferon and cisplatinum, Biol Response Mod, 8, pp. 11-15, (1989)

[8]

Vlock R.D., Johnson J., Myers E., Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck, Head Neck, 13, pp. 15-21, (1991)

[9]

Wadler S., Schwartz E.L., Antineoplastic activity of combination of interferon and cytotoxic agents against experimental and human malignancies: A review, Cancer Res, 50, pp. 3473-3486, (1990)

[10]

Balkwill F.R., Interferons as cell regulatory molecules, Cancer Immunol Immunothcr, 7, pp. 7-14, (1979)

← 1 2 3 →